{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6a13c15d-181a-4a2e-a662-739d0e7f731a/659daeb18aec0c0016fdb260?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Ozempic’s unconventional origins","description":"<p>The runaway success of diabetes and weight-loss drugs Ozempic and Wegovy have turned their maker, Novo Nordisk, into a juggernaut. Last year the Danish drugmaker claimed the title of Europe’s most valuable company. But the development of these drugs was a long, uphill battle.The FT’s global pharmaceutical editor Hannah Kuchler explains how the company’s unique ownership structure played a critical role in the company’s achievements and looks at the&nbsp;challenges ahead.&nbsp;&nbsp;</p><p><br></p><p>Clips from CNBC, CBS, Reuters</p><p>- - - - - - - - - - - - - - - - - - - - - - - - - -&nbsp;</p><p>Subscribe and listen to <strong>Untold: The Retreat</strong> on <a href=\"https://podcasts.apple.com/us/podcast/untold-the-retreat/id1724826952\" rel=\"noopener noreferrer\" target=\"_blank\">Apple Podcasts</a>, <a href=\"https://open.spotify.com/show/1GUc0a6lsMCaTDbgIU4tgJ\" rel=\"noopener noreferrer\" target=\"_blank\">Spotify</a> or wherever you get your podcasts.</p><p>- - - - - - - - - - - - - - - - - - - - - - - - - -&nbsp;</p><p><strong>For further reading:</strong></p><p><a href=\"https://www.ft.com/content/d4d289a7-e1a5-4848-8e7e-b592f7018722\" rel=\"noopener noreferrer\" target=\"_blank\">FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk</a></p><p><a href=\"https://www.ft.com/content/69324884-a626-4787-a4ce-aece410d1dcc\" rel=\"noopener noreferrer\" target=\"_blank\">How anti-obesity drugs built the world’s largest charitable foundation</a></p><p><a href=\"https://www.ft.com/content/8a63fbe6-b8fe-4fb7-9ed4-ca81cf80312f\" rel=\"noopener noreferrer\" target=\"_blank\">Obesity drugs: broadly good for investors, with some strictures</a></p><p><a href=\"https://www.ft.com/content/efeabfcf-4810-4d50-9442-212ab39f3a4a\" rel=\"noopener noreferrer\" target=\"_blank\">Covid-19 vaccine winners suffer reversal of fortune</a></p><p>- - - - - - - - - - - - - - - - - - - - - - - - - -&nbsp;</p><p>On X, follow Hannah Kuchler (<a href=\"https://twitter.com/hannahkuchler\" rel=\"noopener noreferrer\" target=\"_blank\">@hannahkuchler</a>) and Michela Tindera (<a href=\"https://twitter.com/mtindera07\" rel=\"noopener noreferrer\" target=\"_blank\">@mtindera07</a>), or follow Michela on LinkedIn for updates about the show and more.&nbsp;</p><p><br></p><p><a href=\"https://www.ft.com/content/bf1958b8-a0f5-461e-b445-cc9160c6a610\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Read a transcript of this episode on FT.com</strong></a></p>","author_name":"Financial Times"}